FuturedMe announces ¥150m investment from Real Tech Fund IV
The funding supports compound synthesis and biological testing for the company’s CANDDY targeted protein-degradation platform.
FuturedMe announced ¥150 million in funding from Real Tech Fund IV Investment Limited Partnership in a January 9, 2026 release by the fund’s manager, UntroD Capital Japan. The manager identified June 2025 as the investment month.
The money was earmarked for compound synthesis and in vitro and in vivo testing of activity, pharmacology and toxicity. That work supports proof of concept for CANDDY, FuturedMe’s technology for directing disease-related proteins to the proteasome for degradation.
UntroD described itself as the lead investor and said it would support development of the platform. FuturedMe was working to demonstrate selective degradation of proteins associated with cancer and autoimmune disease, with the goal of developing medicines for targets that conventional inhibition approaches struggle to address.
Use of funds
Synthesize compounds and verify activity, pharmacology and toxicity in CANDDY research